In Vitro Anticancer and Cytotoxic Activities of Siddha Formulation Parangi Rasayanam Against Hela Cell Line

Abstract

Background: Cervical cancer is a significant global health concern since it is the fourth most frequent disease in women globally, accounting for about a quarter of a million fatalities each year. Drug resistance, recurrence, and metastasis are the systematic risks associated with conventional therapies. As a result, there is a dire need to develop new drugs with high efficacy and low side effects. Traditional forms of medicine used in India, such as siddha, offer an excellent resource for discovering novel candidates against cervical cancer. Objective: The main aim of the present clinical investigation is to evaluate the anticancer potential of the siddha formulation Parangi rasayanam (PR) against the human cervix adenocarcinoma cell line (HeLa). Methods: Viable HeLa cells were incubated with test drug PR at the concentration of 10, 25, 50, 75, and 100 μg/ml along with standard doxorubicin over a period of time, and the percentage cell viability was ascertained using SRB and MTT assay model. Results:  Results of the SRB assay signifies that PR reveals significant percentage inhibition (33.17) at 100μg/mL. A similar type of inhibition was observed at a lower dose range of PR at 75μg/mL (50), 50μg/mL (75.57), and 25 μg/mL (94.03), respectively. The test drug's activity was compared to conventional doxorubicin (3.5uM/ml), revealing a viability of 49.73%. Results of the MTT assay show that the percentage of cell viability of the HeLa cell line decreases as the concentration of the test substance PR increases. The lowest cell viability was observed at 100µg/ml (31.23%), and the corresponding IC50 value was 75.98 µg/ml. Conclusion: It was concluded from the results of the present investigation that the siddha formulation PR reveals promising anticancer properties against the HeLa cells; further studies need to be elaborated before clinical recommendation of the drug in the future.